June 20, 2023 07:19 AM EDTUpdated 10:41 AM

Bavarian Nordic's purchase of Emergent's late-stage Chikungunya vaccine pays off in PhIII readout

Drew Armstrong

Executive Editor

A late-stage Chikungunya vaccine that Bavarian Nordic bought from Emergent BioSolutions earlier this year has succeeded in a first readout from a Phase III trial …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Bavarian Nordic's purchase of Emergent's late-stage Chikungunya vaccine pays off in PhIII readout

Drew Armstrong

Executive Editor

Sign up to read this article for free.

Sanofi, OpenAI, Formation Bio debut patient recruiting tool, will use in Phase 3 multiple sclerosis studies

Maze's ALS spinout Trace Neuroscience raises $101M for ALS and neuro work

Pfizer looking to sell hospital drugs unit — reports

Novartis pays $150M upfront to Schrödinger in new drug deal, ramps up software use

'Expertise is a real thing': FDA commissioner warns of political risk to agency

What Will It Take to Reverse Fibrosis in Patients with Advanced MASH?

Bavar­i­an Nordic's pur­chase of Emer­gen­t's late-stage Chikun­gun­ya vac­cine pays off in PhI­II read­out

Drew Armstrong

Executive Editor

Sign up to read this article for free.

Sanofi, Ope­nAI, For­ma­tion Bio de­but pa­tient re­cruit­ing tool, will use in Phase 3 mul­ti­ple scle­ro­sis stud­ies

Maze's ALS spin­out Trace Neu­ro­science rais­es $101M for ALS and neu­ro work

Pfiz­er look­ing to sell hos­pi­tal drugs unit — re­ports

No­var­tis pays $150M up­front to Schrödinger in new drug deal, ramps up soft­ware use

'Ex­per­tise is a re­al thing': FDA com­mis­sion­er warns of po­lit­i­cal risk to agency

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

Bavarian Nordic's purchase of Emergent's late-stage Chikungunya vaccine pays off in PhIII readout

Sanofi, OpenAI, Formation Bio debut patient recruiting tool, will use in Phase 3 multiple sclerosis studies

Maze's ALS spinout Trace Neuroscience raises $101M for ALS and neuro work

Pfizer looking to sell hospital drugs unit — reports

Novartis pays $150M upfront to Schrödinger in new drug deal, ramps up software use

'Expertise is a real thing': FDA commissioner warns of political risk to agency

What Will It Take to Reverse Fibrosis in Patients with Advanced MASH?